公开(公告)号：ES2422735T3

公开(公告)日：2013-09-13

申请号：ES07797432

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

Abstract: Un procedimiento para evaluar, en un paciente humano, el riesgo a desarrollar una reacción adversa a unmedicamento en respuesta a un fármaco, que comprende detectar la presencia de HLA-B*1502 en una muestra obtenida del paciente y correlacionar la presencia de HLA-B*1502 en la muestra con un riesgo aumentado de desarrollo de una reacciónadversa a un medicamento en el paciente en respuesta al fármaco, en el que la reacción adversa a un medicamentoes el síndrome de Stevens-Johnson o necrólisis epidérmica tóxica y el fármaco es oxcarbazepina o licarbazepina.

公开(公告)号：BRPI0710436A2

公开(公告)日：2012-10-09

申请号：BRPI0710436

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  LIN HSIN-YU ,  CHENN WEI-HSUAN ,  CHANG CHI-FENG

IPC: C12Q1/68

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

公开(公告)号：WO2007134235A3

公开(公告)日：2008-01-17

申请号：PCT/US2007068782

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC ,  CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

CPC classification number: C12Q1/6881 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/142 ,  C12Q2600/156 ,  C12Q2600/16 ,  C12Q2600/172 ,  Y10T436/143333

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

Abstract translation: 本发明涉及确定某些HLA等位基因如HLA-B * 1502或HLA-B * 5801的存在的方法以及用于实施该方法的试剂盒。 还公开了一种基于遗传标记（例如HLA-B）的存在或不存在来评估患者是否处于发展不良药物反应（例如，史蒂文斯 - 约翰逊综合征，中毒性表皮坏死松解症或超敏反应综合征）的风险中的方法 * 1502，HLA-B * 5801或HLA-B * 4601）。

公开(公告)号：NZ597628A

公开(公告)日：2013-07-26

申请号：NZ59762807

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

Abstract: 597628 Disclosed is a method of assessing a risk of a human patient for developing an adverse drug reaction in response to a drug, comprising: Detecting the presence of HLA-B*5801 in a sample obtained from the patient; and Correlating the presence of HLA-B*5801 in the sample with an increased risk for an adverse drug reaction in the patient in response to the drug, wherein the adverse drug reaction is Stevens-Johnson syndrome or toxic epidermal necrolysis and the drug is oxypurinol.

公开(公告)号：NZ572259A

公开(公告)日：2012-03-30

申请号：NZ57225907

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

Abstract: Disclosed is a method of assessing a risk of a human patient for developing an adverse drug reaction in response to a drug, comprising detecting the presence of HLA-B*1502 in a sample obtained from the patient, and correlating the presence of HLA-B*1502 in the sample with an increased risk for an adverse drug reaction in the patient in response to the drug, wherein the adverse drug reaction is Stevens-Johnson syndrome or toxic epidermal necrolysis and the drug is oxcarbazepine.

公开(公告)号：PL2016198T3

公开(公告)日：2013-12-31

申请号：PL07797432

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

公开(公告)号：AU2013219191A1

公开(公告)日：2013-09-12

申请号：AU2013219191

申请日：2013-08-21

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHANG CHI-FENG ,  SHEN CHIH-LUNG ,  CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  CHEN WEI-HSUAN ,  LIN HSIN-YU

IPC: C12Q1/68

Abstract: The present invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for 5 developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

公开(公告)号：CA2651954A1

公开(公告)日：2007-11-22

申请号：CA2651954

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN WEI-HSUAN ,  LIN HSIN-YU ,  CHANG CHI-FENG ,  SHEN CHIH-LUNG ,  HUNG SHUEN-LU ,  CHEN YUAN-TSONG

IPC: C12Q1/68 ,  C12P19/34 ,  C12Q1/02

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out t his method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the pres ence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B* 4601).

公开(公告)号：CA2651954C

公开(公告)日：2014-02-25

申请号：CA2651954

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68 ,  C12P19/34 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/543

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

公开(公告)号：PT2016198E

公开(公告)日：2013-07-29

申请号：PT07797432

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68